1.0Apple Latesthttps://applelatest.com/enrich600338<blockquote class="wp-embedded-content" data-secret="mGUCm0c7h2"><a href="https://applelatest.com/en/stocks/2728.html">Shares of Sage Therapeutics, which specializes in neurodegenerative diseases, fall after disappointing Parkinson's data</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://applelatest.com/en/stocks/2728.html/embed#?secret=mGUCm0c7h2" width="600" height="338" title="“帕金森病數據令人失望，專注於神經退行性疾病的 Sage Therapeutics 股價下跌” — Apple Latest" data-secret="mGUCm0c7h2" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(c,l){"use strict";var e=!1,o=!1;if(l.querySelector)if(c.addEventListener)e=!0;if(c.wp=c.wp||{},c.wp.receiveEmbedMessage);else if(c.wp.receiveEmbedMessage=function(e){var t=e.data;if(!t);else if(!(t.secret||t.message||t.value));else if(/[^a-zA-Z0-9]/.test(t.secret));else{for(var r,s,a,i=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),n=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),o=0;o<n.length;o++)n[o].style.display="none";for(o=0;o<i.length;o++)if(r=i[o],e.source!==r.contentWindow);else{if(r.removeAttribute("style"),"height"===t.message){if(1e3<(s=parseInt(t.value,10)))s=1e3;else if(~~s<200)s=200;r.height=s}if("link"===t.message)if(s=l.createElement("a"),a=l.createElement("a"),s.href=r.getAttribute("src"),a.href=t.value,a.host===s.host)if(l.activeElement===r)c.top.location.href=t.value}}},e)c.addEventListener("message",c.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",t,!1),c.addEventListener("load",t,!1);function t(){if(o);else{o=!0;for(var e,t,r,s=-1!==navigator.appVersion.indexOf("MSIE 10"),a=!!navigator.userAgent.match(/Trident.*rv:11\./),i=l.querySelectorAll("iframe.wp-embedded-content"),n=0;n<i.length;n++){if(!(r=(t=i[n]).getAttribute("data-secret")))r=Math.random().toString(36).substr(2,10),t.src+="#?secret="+r,t.setAttribute("data-secret",r);if(s||a)(e=t.cloneNode(!0)).removeAttribute("security"),t.parentNode.replaceChild(e,t);t.contentWindow.postMessage({message:"ready",secret:r},"*")}}}}(window,document); </script>本周三，Sage Therapeutics公司（納斯達尅股票代碼：SAGE）公佈了dalzanemdor（SAGE-718）治療帕金森病輕度認知障礙患者的PRECEDENT 2期研究的初步結果。PRECEDENT研究未達到其主要終點，即在第42天時，接受每日一次dalzanemdor治療的患者與接受安慰劑治療的患者在韋氏成人智能量表第四版-IV（WAIS-IV）編碼測試得分上與基線相比有顯著統計學差異。WAIS-IV是https://s.yimg.com/ny/api/res/1.2/ftcaV3Vs8TolbpHooU38AA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MA--/https://media.zenfs.com/en/Benzinga/80edd6624b971a43cf13e51068112dca